Seeking Alpha

Medtronic (MDT) announces one-year results from its first randomized clinical trial...

Medtronic (MDT) announces one-year results from its first randomized clinical trial investigating renal denervation showing patients who initially received treatment with the Symplicity renal denervation system sustained a significant drop in blood pressure compared to baseline at 12 months, plus no device-related serious adverse events, no late vascular complications, and no significant decline in kidney function.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|